

PRESS RELEASE

April 11, 2024

Rottapharm Biotech announces upcoming oral presentation of CR10049 in the inflammatory osteoarthritis (OA) phenotype at the OARSI World Congress on OA

Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that the first preclinical data supporting the advancement of CR10049 (targeted kinase inhibitor for the inflammatory OA phenotype) will be presented in an oral presentation at the upcoming Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, to be held April 18 – 21, 2024 in Vienna, Austria.

Presentation Details

Session: Late Breaking Oral Abstract Podium Session

Abstract Title: CR10049, the first OA-targeted kinase inhibitor, improves pain behaviour, resolves inflammation and preserves joint structure in small and large animal models

Abstract Number: LB-5

Presenting Author: Tiziana Piepoli

Presentation Session Date and Time: Saturday, April 20, 2024, 6:00 p.m. – 6:45 p.m. CEST

The abstract will be published in the June issue of Osteoarthritis and Cartilage. Data presented at the congress will be available to view in this website page following the abstract publication.

CR10049 (kinase inhibitor for the inflammatory OA phenotype)

CR10049 is the lead of a series of small molecules with potent activity on undisclosed selected kinases that play a role in both OA pain (symptom-modifying) and inflammatory joint degeneration (structure-modifying). One such drug would be a major breakthrough in the treatment of inflammatory OA.



Rottapharm Biotech

Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs. It is located in Monza (Italy). The company expertise in research and development includes medicinal/computational chemistry for small molecules, development of biologics and advanced therapies, new targets validation, pharmacological and pharmacokinetic characterization of new drug candidates, original formulations, and design of innovative clinical trials. The company strategy is to develop its own pipeline independently and then seek partnerships with pharmaceutical companies, as well as investing in alliances on innovative projects of other biotech companies or university spin-offs.

Contact

Federica Girolami, Business Development Director

Tel. +39 346 4131428

federica.girolami@rottapharmbiotech.com